No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Autek China Inc. focuses its operations on the entire process from conceptualization and development to the manufacturing and distribution of products related to ocular health and visual care. The company's offerings prominently feature specialized ophthalmic medical devices, including orthokeratology lenses, which are utilized for improving eyesight and managing the progression of short-sightedness. This enterprise was founded in 2001 and is primarily based in Hefei, China.
www.orthok.cnNo one on the platform currently holds 300595.SZ.
No tracked institution reports a position in 300595.SZ as of their last filing.
No one on the platform has traded 300595.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.8% | 20.3% | 34.0% | — | — | — |
| Rev. Growth % | 2.0% | 16.3% | ||||
| Profit Margin % | 25.9% | 35.9% | 42.1% | |||
| Free Cash Flow Margin % | 38.2% | 33.4% | 31.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.9B | +7.1% | $0.52 | $0.51–$0.53 | — | 1 |
| 2027 | $2.1B | +8.3% | $0.55 | $0.53–$0.56 | — | 1 |
| 2028 | $2.3B | +13.0% | $0.60 | $0.59–$0.62 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-29 | $0.12 | $0.12 | +0.0% |
| 2026-03-27 | $0.10 | $0.10 | +0.0% |
| 2025-10-24 | $0.23 | $0.21 | -7.6% |
| 2025-08-22 | $0.13 | $0.10 | -21.6% |
| 2025-04-22 | $0.23 | $0.18 | -21.7% |
| 2025-03-28 | $0.11 | $0.06 | -45.5% |
| 2024-10-25 | $0.21 | $0.22 | +4.8% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300595.SZAutek China Inc. | $9.95 | +0.51% | $8.9B | — |
| 000403.SZPacific Shuanglin Bio-pharmacy Co., Ltd. | $9.94 | -0.60% | $9.4B | — |
| 002020.SZZhejiang Jingxin Pharmaceutical Co., Ltd. | $11.38 | -0.70% | $9.8B | — |
| 300171.SZTofflon Science and Technology Group Co., Ltd. | $13.75 | +0.00% | $10.5B | — |
| 300529.SZJafron Biomedical Co.,Ltd. |
| $14.92 |
| +0.40% |
| $11.9B |
| — |
| 300573.SZShenyang Xingqi Pharmaceutical Co.,Ltd | $36.41 | +0.86% | $13.0B | — |
| 301015.SZQingdao Baheal Medical Inc. | $23.01 | -2.13% | $12.1B | — |
Source: Financial Modeling Prep · peers by sector/industry